Clinical trials: Metastatic Kidney Cancer
Locally Advanced and/or Metastatic Renal Cell Carcinoma, Carcinoma, Renal Cell
First Line Pazopanib in Poor Risk Patients With Metastatic Renal Cell Carcinoma
Patients with advanced renal cell carcinoma (RCC) are classified according to Memorial Sloan-Kettering Cancer Center (MSKCC) criteria in three risk-groups: favourable, intermediate and poor.
- Conditions
- Locally Advanced and/or Metastatic Renal Cell Carcinoma, Carcinoma, Renal Cell, Clear-cell Metastatic Renal Cell Carcinoma
- Trial name
- FLIPPER (NCT01521715)
- Testing
- Pazopanib
- Where
- 8 sites in Germany
- Volunteers
- 44 people
- Sponsor
- iOMEDICO AG
Urothelial Carcinoma
A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer
The main purpose of this study is to evaluate the safety and efficacy of the study drug ramucirumab in combination with docetaxel in participants with urothelial cancer who failed prior platinum-based therapy.
- Trial name
- RANGE (NCT02426125)
- Testing
- Ramucirumab, Docetaxel
- Where
- 141 sites in United States, Australia and 21 more
- Volunteers
- 530 people
- Sponsor
- Eli Lilly and Company
Secondary (AA) Amyloidosis, Rheumatoid Arthritis
Study of the Safety and Efficacy of NC-503 in Secondary (AA) Amyloidosis
The main objective of this study is to evaluate the safety and efficacy of NC-503 compared to placebo in patients with secondary (AA) amyloidosis using a composite assessment of clinical improvement/worsening of both renal and…
- Conditions
- Secondary (AA) Amyloidosis, Rheumatoid Arthritis, Nephrotic Syndrome, Familial Mediterranean Syndrome
- Trial name
- NCT00035334
- Testing
- NC-503 (Anti-amyloidotic (AA) Agent)
- Where
- 26 sites in United States, Finland and 10 more
- Volunteers
- 150 people
- Sponsor
- Bellus Health Inc. - a GSK company
Advanced Solid Tumors
Study of Intermittent OSI-906 Dosing
Multicenter, open-label, phase 1, cohort dose escalation study to determine the maximum tolerated dose (MTD) of 3 intermittent OSI-906 dosing schedules.
- Trial name
- NCT00514306
- Testing
- OSI-906
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 79 people
- Sponsor
- Astellas Pharma Inc
Carcinoma, Renal Cell
Study of Lenvatinib in Combination With Everolimus in Participants With Unresectable Advanced or Metastatic Renal Cell Carcinoma (RCC)
Phase 1 study to investigate the tolerability and safety of lenvatinib in combination with Everolimus in participants with unresectable advanced or metastatic RCC.
- Trial name
- NCT02454478
- Testing
- Lenvatinib, Everolimus
- Where
- 3 sites in Japan
- Volunteers
- 7 people
- Sponsor
- Eisai Co., Ltd.
Advanced Solid Tumors
A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803 in Patients With Advanced Solid Tumors
The proposed clinical trial is a phase I, open-label, multi-center, dose-escalation study of ALT-803 in patients with surgically incurable advanced solid tumors: melanoma, renal cell, non-small cell lung and squamous cell head…
- Trial name
- NCT01946789
- Testing
- ALT-803
- Where
- 5 sites in United States
- Volunteers
- 26 people
- Sponsor
- Altor BioScience
Papillary Renal Cell Carcinoma
Real World Study of Effectiveness of Sunitinib or Sorafenib to Chinese Unresectable Locally Advanced or Metastatic PRCC
This is a multi-center, observational, retrospective study designed to characterize the effectiveness and safety of sunitinib or sorafenib monotherapy in the treatment of Chinese adult patients with unresectable and locally…
- Trial name
- PRCC (NCT07024680)
- Testing
- Observational, None intervention
- Where
- China
- Volunteers
- 48 people
- Sponsor
- AstraZeneca
Bladder Cancer
Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer
The purpose of this study is to determine whether Patients with Locally Advanced or Metastatic Bladder Cancer who receive Eribulin Mesylate Administered in Combination with Gemcitabine Plus Cisplatin Versus Gemcitabine Plus…
- Trial name
- NCT01126749
- Testing
- Gemcitabine, E7389, Cisplatin
- Where
- 42 sites in United States, Germany and 4 more
- Volunteers
- 92 people
- Sponsor
- Eisai Inc.
Advanced Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma
Study of Cabozantinib as Monotherapy or in Combination With Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma Under Real-life Clinical Setting in 1st Line Treatment.
The purpose of the protocol, is to describe the use of cabozantinib tablets as monotherapy or in combination with nivolumab including the number of dose reductions, dose interruptions and terminations due to (serious) adverse…
- Trial name
- CABOCARE (NCT03647878)
- Where
- 82 sites in Austria, Germany
- Volunteers
- 224 people
- Sponsor
- Ipsen
Multiple Indications Cancer
Study to Assess the Safety of Nivolumab in the Treatment of Metastatic Melanoma, Lung Cancer, Renal Cancer, Squamous Cell Carcinoma of the Head and Neck, and Chronic Hodgkin Lymphoma in Adults in Mexico
This is a post-marketing study of patients who started nivolumab as first- or second-line therapy for metastatic melanoma or as second-line therapy for metastatic squamous non-small cell lung cancer (SqNSCLC) , metastatic…
- Trial name
- NCT03161613
- Testing
- Non-Interventional
- Where
- Mexico
- Sponsor
- Bristol-Myers Squibb
Carcinoma, Renal Cell
SU011248 Versus Interferon-Alfa As First-Line Systemic Therapy For Patients With Metastatic Renal Cell Carcinoma
The purpose of this study is to test whether SU011248 has activity and is safe compared to interferon-alfa as first-line therapy in patients with metastatic renal cell carcinoma (RCC).
- Trial name
- NCT00083889
- Testing
- Interferon-alfa, SU011248
- Where
- 123 sites in United States, Australia and 9 more
- Volunteers
- 750 people
- Sponsor
- Pfizer
Urothelial Carcinoma, Renal Cell Carcinoma
Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
This is a multicenter Phase 1b, open-label study to assess safety, tolerability, preliminary efficacy, and pharmacokinetics (PK) of cabozantinib taken in combination with atezolizumab in subjects with multiple tumor types…
- Conditions
- Urothelial Carcinoma, Renal Cell Carcinoma, Non-Small Cell Lung Cancer, Castration-resistant Prostate Cancer
- Trial name
- NCT03170960
- Testing
- cabozantinib, atezolizumab
- Where
- 124 sites in United States, Australia and 7 more
- Volunteers
- 914 people
- Sponsor
- Exelixis
Metastatic Renal Cell Carcinoma
Everolimus as Second-line Therapy in Metastatic Renal Cell Carcinoma
This study will evaluate everolimus as second-line therapy in patients with metastatic renal cell carcinoma. Each patient will be enrolled and stratified in one of three cohorts based upon their first-line therapy: 1) prior…
- Trial name
- RECORD-4 (NCT01491672)
- Testing
- RAD001
- Where
- 17 sites in United States, Argentina and 4 more
- Volunteers
- 134 people
- Sponsor
- Novartis Pharmaceuticals
Renal Cell Carcinoma
CTT1057, a Small Molecular Inhibitor of PSMA, as a Novel Imaging Agent of Neovascularization in Renal Cell Carcinoma
The purpose of this study is to test a novel diagnostic PET imaging agent for safety and biodistribution. The agent binds PSMA and is designed to detect Prostate Specific Membrane Antigen expressing tumors, such as has been…
- Trial name
- NCT03427476
- Testing
- CTT1057
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Cancer Targeted Technology
Metastatic Renal Cell Carcinoma
Study Using FolateScan to Identify Subjects With Folate Receptor-Positive Metastatic Renal Cell Carcinoma
Phase 2, multi-center, open-label, single-treatment group, baseline-controlled study to identify subjects with Folate Receptor-Positive Metastatic Renal Cell Carcinoma
- Trial name
- NCT01689766
- Testing
- Technetium Tc 99m EC20
- Where
- 2 sites in United States
- Volunteers
- 150 people
- Sponsor
- Endocyte
Renal Cell Carcinoma
A Study of Recombinant Vaccinia Virus in Combination With Cemiplimab for Renal Cell Carcinoma
This is a Phase 1b/2a, open-label, multi-center, dose-escalation and safety/efficacy evaluation trial of Pexa-Vec plus Cemiplimab in patients with metastatic or unresectable renal cell carcinoma (RCC).
- Trial name
- NCT03294083
- Testing
- Pexastimogene Devacirepvec (Pexa-Vec), Cemiplimab
- Where
- 21 sites in United States, Australia and 1 more
- Volunteers
- 95 people
- Sponsor
- SillaJen, Inc.
Advanced Solid Tumors, Metastatic Renal Cell Carcinoma
M8891 First in Human in Solid Tumors
The purpose of this study was to determine the maximum tolerated dose (MTD), safety, tolerability, Pharmacokinetic (PK), pharmacodynamic and clinical activity of M8891 as single agent in participants with advanced solid tumors in…
- Trial name
- M8891 (NCT03138538)
- Testing
- Part 1: M8891
- Where
- 7 sites in United States
- Volunteers
- 27 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Melanoma, Kidney Neoplasms
Study of Interleukin-21 for Metastatic Malignant Melanoma and Metastatic Kidney Cancer
This study is being done to see if an experimental drug called recombinant interleukin-21 (rIL-21) when given to patients with stage 4 malignant melanoma or stage 4 kidney cancer is safe and has any effect on these types of…
- Conditions
- Melanoma, Kidney Neoplasms, Metastases
- Trial name
- NCT00095108
- Testing
- Recombinant Human Interleukin-21
- Where
- 2 sites in United States
- Volunteers
- 43 people
- Sponsor
- ZymoGenetics
Metastases, Neoplasm, Carcinoma, Non-small Cell Lung
A Study of LY2584702 With Erlotinib or Everolimus in Participants With Solid Tumors
Study I3G-MC-JGCB (JGCB) is a multicenter, nonrandomized, open-label, dose-escalation Phase 1b study of LY2584702 in combination with either erlotinib or everolimus.
- Conditions
- Metastases, Neoplasm, Carcinoma, Non-small Cell Lung, Renal Cell Carcinoma, Neuroendocrine Tumors
- Trial name
- NCT01115803
- Testing
- LY2584702, Erlotinib, Everolimus
- Where
- 3 sites in United States, France
- Volunteers
- 29 people
- Sponsor
- Eli Lilly and Company
Renal Cell Carcinoma, Non-small Cell Lung Cancer
Study of RO7515629 in Participants With HLA-G Positive Solid Tumors
The main purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, immune response and preliminary anti-tumor activity of RO7515629 alone in participants with advanced or metastatic solid tumors expressing…
- Conditions
- Renal Cell Carcinoma, Non-small Cell Lung Cancer, Pancreatic Adenocarcinoma, Colorectal Cancer
- Trial name
- NCT05769959
- Testing
- RO7515629, tocilizumab
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- Hoffmann-La Roche